Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Last trade$22.91
Day change-$0.39 (-1.67%)
Day range$21.41 – $23.71
Volume214,759
Market cap$482M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$482.33M
Price / earnings
—
Price / book
1.36×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.18×
Profitability
Earnings per share
-$5.76
Return on assets
-31.54%
Return on equity
-33.59%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
19.97×
Quick ratio
19.97×
Cash ratio
4.35×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$97.53M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NGNE, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$8.85M
$11.2M
$8.2M
$6.89M
$6.56M
$6.72M
$8.16M
$6.17M
Research and development
$23.52M
$25.47M
$25.15M
$20.64M
$17.24M
$19.37M
$17.76M
$15.35M
Total operating expenses
$32.38M
$36.67M
$33.35M
$27.53M
$23.8M
$26.08M
$25.92M
$21.51M
Operating income
-$32.38M
-$36.67M
-$33.35M
-$27.53M
-$23.8M
-$26.08M
-$25.92M
-$21.51M
Interest expense
-$29K
$0
$0
-$1K
-$43K
-$1K
-$2K
-$2K
Income before taxes
-$29.02M
-$34.49M
-$30.93M
-$24.74M
-$20.95M
-$22.02M
-$22.65M
-$19.51M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$29.02M
-$34.49M
-$30.93M
-$24.74M
-$20.95M
-$22.02M
-$22.65M
-$19.51M
Net income attributable to common shareholders
-$29.02M
-$34.49M
-$30.93M
-$24.74M
-$20.95M
-$22.02M
-$22.65M
-$19.51M
EBITDA
-$31.56M
-$35.86M
-$32.5M
-$26.75M
-$23.03M
-$25.33M
-$25.17M
-$20.73M
Basic earnings per share
-$1.05
-$1.53
-$1.39
-$1.12
-$0.99
-$1.05
-$1.08
-$1.00
Diluted earnings per share
-$1.05
-$1.53
-$1.39
-$1.12
-$0.99
-$1.05
-$1.08
-$1.00
Recent news
Company coverage with links to the original publishers.
Neurogene (NGNE) closed at $25.28 with a mean analyst price target of $76.67, suggesting 203.3% upside potential. The stock has gained 17.3% over the past four weeks. While price targets should be treated with skepticism, the company shows positive earnings estimate revisions and holds a Zacks Rank #2 (Buy) rating, indicating potential near-term upside.
Acadia Pharmaceuticals generated $576 million in first-half 2026 revenues, up 13% year-over-year, and raised its full-year 2026 guidance to $1.24-$1.30 billion. Nuplazid sales grew 7% to $350.1 million with patent protection until February 2038, while Daybue sales jumped 25% to $226 million, driven by the new STIX formulation and EU approval for Rett syndrome treatment. However, ACAD shares have underperformed the industry by 27.3% year-to-date and face increasing competition from rivals like Axsome and Neurogene.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.